Everolimus got approved by the FDA for the treatment of inoperable, locally advanced or metastatic neuroendocrine tumors of gastrointestinal or lung origin.
Lung and esophageal cancer survivors may not get benefit from radioactive imaging tests used to diagnose cancer recurrence, a new study reveals.
AstraZeneca‘s new drug durvalumab brings hope to bladder cancer patients receiving breakthrough therapy designation by the US FDA.
Patients with resectable pancreatic cancer benefited from receiving at least 6 months of adjuvant chemotherapy, a new study suggests.
Novartis’ investigational drug, midostaurin, received breakthrough therapy designation for US regulators for acute myeloid leukemia.
Researchers report that post-operative colonoscopy is critically important for colorectal cancer patients to avoid cancer resection.
A report on active surveillance of low-risk prostate cancer patients clarifies who should undergo "active surveillance” instead of prostatectomy or radiation.
Cancer patients undergoing chemotherapy should be made aware of the increased risk of heart problems related to chemotherapy’s toxic effects.
A new analysis reveals that minimally invasive hysterectomy appears to be safe for women with endometrial cancer.
EU regulators approved osimertinib for the treatment of adult patients with a specific mutation-positive non-small cell lung cancer.
Breast or thyroid cancer survivors are more likely to develop the other type later in life compared to women with no breast or thyroid cancer history.
A new immunotherapy-related therapeutic approach against multiple myeloma induced record-level clinical results, researchers reveal.
Adult cancer survivors are at increased risk of cardiovascular disease, a new U.S. study finds. Moreover, survivors of certain cancers face a higher risk.
A new study reveals that interrupting radiation therapy during cancer treatment may lead to cancer recurrence, especially for head and neck cancers.
Pediatric acute lymphoblastic leukemia patients treated with chemotherapy alone remain at risk for attention and learning problems later, researchers report.
Adding carfilzomib to the treatment of relapsed and/or refractory multiple myeloma with bortezomib and lenalidomide induced positive results, a new study shows.
Treatment with proton radiotherapy in childhood brain cancer resulted in fewer side effects and similar survival rates as conventional radiotherapy.
Breast reconstruction with fat injection proved to be safe for women with recurrent breast cancer, according to a new study.
Ramucirumab received approval by the European Commission to be used as a treatment for advanced non-small cell lung cancer and metastatic colorectal cancer.
Eisai’s breast cancer drug eribulin mesylate (Halaven) received FDA’s approval to treat patients with liposarcoma.
Docetaxel chemotherapy will be made available to newly diagnosed advanced prostate cancer patients in England, the NHS has announced.
One large study assessing breast cancer survivors’ smoking habits both before and after diagnosis reports that quitting smoking after diagnosis lowers risk of death.
UK’s regulators have recommended olaparib for adult patients with relapsed platinum-sensitive ovarian, fallopian tube and peritoneal cancer.
Using panitumumab with best supportive care to treat metastatic colorectal cancer patients induced positive outcomes, according to a phase 3 study.
Afatinib improved progression-free survival and response in non-small cell lung cancer patients with common epidermal growth factor mutations and brain metastases.
NICE recommends nivolumab as a treatment for advanced, unresectable or metastatic melanoma.
US regulators approved the combination of nivolumab plus ipilimumab for the treatment of unresectable or metastatic melanoma.
A new analysis reveals that ER-positive (ER+) breast cancer may return even after more than 24 years of follow-up.
Pembrolizumab and nivolumab, two targeted immunotherapies, appeared effective in advanced gastric and esophageal cancers, two trials revealed.
Patients with locally advanced bladder cancer lived longer when treated with adjuvant chemotherapy following cystectomy, a new large study shows.